Pancreatic adenocarcinoma

By W. Schima, A. Ba-Ssalamah, C. Kölblinger, C. Kulinna-Cosentini, A. Puespoek, P. Götzinger. European Radiology, 2006

1,961 citations recorded by the source corpus.

Subfields: Oncology, Radiology, Nuclear Medicine and Imaging, Surgery

View Paper: https://www.semanticscholar.org/paper/efbda10616ece3409e2452f40419f28470399c41

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

1. Hans Clevers
2. Giulia Biffi
3. E. White
4. D. Tuveson
5. Alec C. Kimmelman
6. D. Öhlund
7. Ela Elyada
8. Rakesh K. Jain

In Radiology, Nuclear Medicine and Imaging

1. Hans Clevers

In Surgery

1. Hans Clevers
2. Alec C. Kimmelman

Citations in the corpus

• Single-cell RNA-seq highlights intra-tumoral heterogeneity and malignant progression in pancreatic ductal adenocarcinoma (2019, background): “Unfortunately, none of these findings have been translated into clinical use, mainly due to the very limited knowledge about their potential role during PDAC progression, whereas most patients were already at advanced stages at the time of diagnosis.(9) Although initiation- and metastasis-specific m”
• Recent insights into the function of autophagy in cancer (2016, background): “A defining feature of PDAC is its hypovascular and fibrotic microenvironment that promotes conditions of extreme hypoxia and nutrient deprivation (Ryan et al. 2014).”
• Hypoxic Tumor-Derived Exosomal miR-301a Mediates M2 Macrophage Polarization via PTEN/PI3Kγ to Promote Pancreatic Cancer Metastasis. (2018, background): “Although appropriate surgical resection and adjuvant treatments such as chemotherapy are used to treat PC, an overall 5-year survival rate is still less than 5% and the median survival is only about 3-6 months (2,3).”
• Organoid Models of Human and Mouse Ductal Pancreatic Cancer (2014, background): “85% of pancreatic cancer patients are ineligible for surgical resection of their tumors (Ryan et al., 2014).”
• Integrated Genomic Characterization of Pancreatic Ductal Adenocarcinoma (2017, neutral): “Pancreatic ductal adenocarcinoma (PDAC) is an aggressive disease that typically presents at an advanced stage and is refractory to most treatment modalities (Ryan et al., 2014; Wolfgang et al., 2013).”